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ADP-ribosylation is an important post-translational modiﬁcation that plays a pivotal role in many cellular
processes, including cell signaling, DNA repair, gene regulation and apoptosis. Although chemical syn-
thesis of mono- or poly-ADP-ribosylated biomolecules is extremely diﬃcult due to the challenges in
regio- and stereoselective glycosylation, suitable protective group manipulations and pyrophosphate con-
struction, synthetic procedures towards these bio-related targets have been reported in recent years.
Chemically synthesized well-deﬁned ADP-ribose derivatives serve as useful tools in biological experi-
ments aimed to further elucidate native ADP-ribosylation. In this review, we will discuss the synthetic
studies on mono-ADP-ribosylated proteins and oligo-ADP-ribose chains. Future possible synthetic
targets and upcoming new methods for the synthesis of these molecules are also included.
1. Introduction
ADP-ribosylation is a post-translation modification of proteins
that occurs upon enzymatic transfer of the ADP-ribosyl moiety
from NAD+ to a nucleophilic side chain of an amino acid of a
protein.1–3 As a result either mono-ADP-ribose (MAR) or oligo-
ADP-ribose (PAR) becomes grafted to the protein (Fig. 1). Both
modifications play an important regulatory role in various
physiological and pathological processes.4 The transfer of PAR
to amino acids on protein substrates is catalyzed by four
enzymes of the PARP family: PARP1, PARP2, and PARP5a, and
PARP5b. PAR can exist as a linear or branched polymer. Other
PARP family members (PARP3, 4, 6–12, and 14–16) transfer
only MAR to amino acids on protein substrates. Upon ADP-
ribosylation of cellular proteins, either mono- or polymers, the
posttranslational modification becomes subject to further
recognition and processing by proteins that are capable of
removing or binding PAR or MAR (Fig. 1).1 Such variations of
the ADP-ribosylation state result in a change of the intracellu-
lar signaling. Hydrolases such as PARG and enzymes from the
ARH-family are responsible for the breakdown of PAR and
MAR and thus for the reversal of ADP-ribosylation.5,6
From the point of view of a bioorganic chemist, both
mono-ADP-ribosylated (MARylated) and poly-ADP-ribosylated
(PARylated) biopolymers (Fig. 1) present a significant chal-
lenge. Nevertheless, synthetic well-defined ADP-ribosylated
proteins or their substructures are useful for the studies that
are aimed at elucidation of the biological role of ADP-ribosyla-
tion. This review describes the synthetic advances towards the
synthesis of mono-ADP-ribosylated proteins and oligo-ADP-
ribose chains.
2. Chemical synthesis of mono-
ADPr-peptides and ADPr-oligomers
The organic synthesis of ADP-ribosylated biomolecules is chal-
lenging as the construction of these hybrid structures requires
the use of elements from the synthetic chemistry of nucleic
acids, oligosaccharides and oligopeptides that are sometimes
incompatible. The synthetic challenge is augmented by the
necessity to introduce one or even multiple pyrophosphate lin-
kages, which are notoriously diﬃcult to construct eﬃciently.
In the following sections we describe synthetic approaches to
the primary challenges of chemical ADP-ribosylation, that is,
ribosylation of side chains of various amino acids (Fig. 2,
feature A) that culminates in the synthesis of mono-ADP-ribo-
sylated proteins, stereoselective glycosylation of the 2′-OH of
adenosine (Fig. 2, feature B) and assembling the oligo-sugar
pyrophosphate chain of oligo-ADPr (Fig. 2, feature C).
2.1 Synthesis of mono-ADP-ribosylated peptides
Mono-ADP ribosylated proteins play intriguing roles in many
cellular processes.7 An approach to deepen the insight into
these processes to a molecular level comprises the design, syn-
thesis and biological evaluation of well-defined synthetic
mono-ADP-ribosylated derivatives. Relevant examples of such
compounds are mono-ADP-ribosylated oligopeptides,8–10 as
fragments of the naturally occurring proteins. The main chal-
lenges in the assembly of these ADP-ribosylated oligopeptides
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are an eﬃcient procedure for the introduction of the pyropho-
sphate function and a method for the stereoselective
α-ribosylation of the nucleophilic side chains of amino acids.
In this section we will focus on the construction of the
α-glycosidic bond that joins the “distal” ribose of the ADPr-
moiety and an amino acid side chain in the context of the
mono-ADPr-peptide synthesis. The methods that have been
developed for the introduction of one pyrophosphate linkage
in mono-ADP-ribosylated peptides will be discussed in this
section while the introduction of multiple pyrophosphates in
short fragments of poly-ADPr is the subject of discussion in
section 2.2.2. Application of a solid phase approach to mono-
ADP-ribosylated oligopeptides is most obvious as a solution
phase synthesis would be restricted in terms of the length and
composition of the oligopeptide. While the introduction of the
pyrophosphate moiety is feasible on a solid support,8,9 ribosy-
lation of partially protected and immobilized oligopeptides
with a protected ribose donor is almost impossible in terms of
stereoselectivity and yield. Therefore, attention has been
focused on the synthesis of suitably protected ribosylated
amino acid building blocks that can be applied in solid phase
peptide synthesis (SPPS). The main hurdle in the synthesis of
these ribosylated amino acid building blocks is the diﬃculty
to control the 1,2-cis configuration of the ribosyl anomeric
linkage at the glycosylation stage. The sensitivity of this
O-glycosidic bond to an acid adds another layer of complexity.
The first reported synthesis of suitably protected
α-ribosylated amino acid building blocks and their application
in a SPPS assembly of relevant ADP-ribosylated oligopeptides
is by van der Heden van Noort et al.8 The choice for Fmoc-
based peptide synthesis led to the synthesis of protected
α-ribosylated asparagine (Asn) 5 and glutamine (Gln) 6 build-
ing blocks (Scheme 1). The route of synthesis started with the
reduction of fully protected β-D-ribosylated azide 1 to an epi-
meric hemiaminal mixture 2. Subsequently, EDC-mediated
coupling with Z-Glu-OBn and Z-Asp-OBn, respectively and
silica gel purification gave the individual anomers 3 and 4.
Protective group manipulation provided α-ribosylated Asn (5)
and Gln (6) building blocks with the mutually orthogonal
TBDPS and Fmoc protecting groups. Guided by the outcome of
a solution phase study, SPPS was undertaken in which two pro-
cedures for the installation of the adenosine diphosphate func-
tion were explored. For that purpose, native11 model peptide
11 containing an ADP-ribosylated Asn residue and peptide 15
originating from the N-terminus of human histone H2B con-
taining an ADP-ribosylated Gln residue were selected. In the
latter case Gln was chosen as a stabilized isostere of Glu that
was reported to be the natural ADP-ribosylation site.12
Hexapeptide 7 was obtained via SPPS using a BOP/HOBT
Fmoc-based synthesis executed on Tentagel resin equipped
with an HMBA linker. Upon removal of the TBDPS group at
the 5-OH of the ribose, the immobilized peptide 7 (R = H) was
phosphitylated with phosphoramidite 8 under the influence of
the activator DCI, followed by oxidation using iodine in pyri-
dine to give the activated phosphorimidazolate 9. A reaction
with the protected adenosine phosphate 10 led to the for-
mation of the protected and immobilized target ADP-ribosy-
lated peptide. Removal of the Dmab group on Glu and sub-
sequent treatment with ammonia methanol, to aﬀect both the
removal of the remaining protecting groups and cleavage from
the resin, gave after HPLC purification ADP-ribosylated hexa-
peptide 11. With the aid of LC-MS analysis of the crude
product the C-terminal carboxamide, the ribosyl 5-phospho-
monoester and the corresponding H-phosphonate could be
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identified as side products. It was reasoned that the formation
of H-phosphonate could be suppressed by the reversal of the
procedure for pyrophosphate formation. To this end the phos-
phate was installed on the immobilized peptide (i.e. 13), while
activated phosphorimidazolate (i.e. 14) was prepared in solu-
tion. The assembly of ADP-ribosylated peptide 15 started with
Fig. 1 Biosynthesis and metabolism of mono- and poly-ADP-ribosylated proteins.
Fig. 2 Structure of poly-ADP-ribose with its most conspicuous synthetically challenging features.
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the SPPS of heptapeptide 12 according to the same procedure
as described for hexapeptide 7. Protective group manipulation
led to 12 (R′ = Ac, R = H) having only base labile protecting
groups. The phosphate moiety was introduced by phosphityla-
tion with 8 under the influence of the activator DCI, oxidation
of the intermediate phosphite triester with t-BuO2H and,
finally, removal of the p-methoxybenzyl groups with TFA to
give phosphomonoester 13. Immobilized 13 was now treated
with an excess of activated phosphorimidazolate 14 to aﬀord
the immobilized and protected precursor of target 15.
The removal of all protecting groups and concomitant clea-
vage from the resin gave ADP-ribosylated heptapeptide 15.
However, also with this procedure the unwanted formation of
the phosphate monoester (from intermediate 13) and the
corresponding H-phosphonate could not be circumvented. In
spite of the successful application of the α-ribosylated aspara-
gine 5 and glutamine 6 building blocks in SPPS and the iso-
lation of pure ADP-ribosylated peptides 11 and 15 in reason-
able yields, it became apparent that the assembly of ADP-ribo-
sylated peptides would benefit from a more eﬃcient procedure
for pyrophosphate formation.
Other authors also undertook the synthesis of protected
α-ribosylated asparagine and glutamine building blocks. Thus,
Bonache et al.13 have prepared such a derivative for the first
time, while F. Nisic et al.14,15 developed a stereoselective syn-
thesis of α- or β-glycofuranosyl amides with the aid of traceless
Staudinger ligation of glycofuranosyl azides. Application of
this approach for the synthesis of α-N-ribosyl-asparagine/gluta-
mine building blocks is depicted in Scheme 2.16
Fluorinated triphenylphosphines functionalized with
Z-Asp-OBn (17) and Z-Glu-OBn (18) were used in ligation reac-
tions with diﬀerently protected β-D-ribofuranosyl azides. It
turned out that both stereochemistry and productivity of these
reactions were dependent on the protection of the hydroxyl
groups in the ribose moiety. Protection of the primary 5-OH
with the TBDPS group (16) produced (Asn) 19 and (Gln) 20 in
good yields. Subsequent acetylation of 19 and 20 gave known8
SPPS building blocks 3 and 4.
Scheme 1 Synthesis of ADP ribosylated peptides 11 and 15.
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With the aim of broadening the range of the synthetically
accessible ribosylated amino acids Kistemaker et al.17 devel-
oped an alternative ribosylation method that employed ribosyl
donors 21a, b, and c (Scheme 3) with the N-phenyl trifluoro-
acetimidate leaving group and with non-participating ether
protecting groups at 3- and 2-OH. The latter feature allows the
formation of both O- and N-glycosidic linkages via highly
α-selective acid catalyzed glycosylation. Condensation of per-
benzylated donor 21c with Asn acceptor 22 (R3 = Cbz) under
various conditions led to α-product 28c (n = 1). However, these
conditions were not transferable to other acceptors (e.g. Glu
acceptor 23 (R3 = Cbz)). It was reasoned that the selectivity of
the ribosylation could be improved by replacing the benzyl
group at the 5-OH in the ribose by the bulkier TBDPS or TIPS
protecting groups to give donor 21b (R1 = TBDPS or TIPS).
Several activator systems were tested and the results of these
tests indicated that TMSOTf and HClO4-SiO2 were the most
favorable activators. A reaction of donor 21b (R1 = TBDPS or
TIPS) with Asn acceptor 22 (R3 = Cbz) and Gln acceptor 23
(R3 = Cbz) gave good to excellent yields of α-products 28b (n =
1, 2, respectively). Next, this glycosylation protocol was applied
to Cbz- and Fmoc-protected glutamic acid (Glu, 26), aspartic
acid (Asp, 25) and serine (Ser, 27). Using TMSOTf as activator
protected derivatives of ribosylated Asp 30 (n = 1, α/β = 98:2,
51%), ribosylated Glu 30 (n = 2, α/β = 98 : 2, 59%) and ribosy-
lated Ser 31a (R1 = TBDPS, α/β = 1 : 0, 60%) were obtained.
In order to minimize protecting group manipulations
towards the ribosylated amino acid building blocks suitable
for SPPS, the benzyl groups at the 2-OH and 3-OH in the
ribosyl donor were replaced with acid labile PMB ethers and
Scheme 2 Synthesis of α-ribofuranosyl amides using ﬂuorinated phosphines.
Scheme 3 Triﬂuoroacetimidate ribosylation of partially protected amino acids.
Review Organic & Biomolecular Chemistry
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the Cbz group in the amino acid acceptors was replaced with
the Fmoc group. Condensation of imidate donor 21a (R1 =
TBDPS) with Asn acceptor 22 (R3 = Fmoc) in DCM under the
influence of TMSOTf furnished 28a (n = 1, α/β = 97 : 3, 79%). A
similar condensation using the less nucleophilic citrulline
(Cit) acceptor 24 proceeded in a less α-selective manner to give
29 (α/β = 78 : 22, 40%). The insolubility of Gln acceptor 23 (R3
= Fmoc) required a change to dioxane/DCM as the solvent
system and HClO4-SiO2 as the activator to give 28a (n = 2, α/β =
93 : 7, 69%). Finally, condensation of Ser acceptor 27 (R3 =
Fmoc) with donor 21a (R1 = TIPS) furnished ribosylated Ser
31b (α/β = 1 : 0, 75%).
To obtain relevant ADP-ribosylated oligopeptides by SPPS,
Kistemaker et al.9,18 also searched for another procedure for
pyrophosphate formation. To this end, the solution phase
method for the synthesis of sugar nucleotides, reported by
Gold et al.,19 was adopted. This procedure9 combines phos-
phoramidite (PIII) with phosphate (PV) chemistry and the adap-
tation to a solid phase procedure required the on-resin for-
mation of a phosphomonoester. It was reasoned that this
could be circumvented by the development of the protected
pre-phosphorylated amino acid building blocks 34–37
(Scheme 4). The synthesis of these phosphorylated amino
acids is illustrated by the preparation of Asn building block 34.
The PMB groups in fully protected ribosylated Asn 32 were
replaced by acetyl groups by acidolysis, followed by acetylation
while 5-OH was unmasked by desilylation to aﬀord 33. The
tert-butyl group was selected as an orthogonal phosphate pro-
tecting group.
The di-tert-butyl phosphate triester was installed with di-
tert-butyl N,N-diisopropylphosphoramidite and subsequent
oxidation of the intermediate phosphite triester. Finally,
hydrogenolysis of the benzyl ester gave the α-configured Asn
building block 34 suitable for SPPS. Transferring this pro-
cedure to other amino acids showed that the anomeric integ-
rity of Gln 35 and Ser 37 remained intact while Cit 36 was
obtained as an anomeric mixture, which could be separated by
column chromatography.
With these building blocks available SPPS could be under-
taken and relevant ADP-ribosylated oligopeptide fragments
from Histone H2B, RhoA protein and HNP-1 defensin were
obtained.9 The synthesis of Ser-ADPr H2B peptide 42
(Scheme 5) serves as a representative example of the usefulness
of this methodology for the preparation of ADP-ribosylated
peptides with a native ADP-ribosylation site.10 The SPPS of
hendecapeptide 42 was carried on Tentagel resin, equipped
with an HMBA-linker. First, intermediate immobilized hepta-
peptide 38 was produced with automated SPPS utilizing Fmoc
chemistry and trifluoroacetyl protected lysine residues.
Subsequent elongation to phosphoribosylated peptide 39 was
done manually using serine phosphotriester 37 and commer-
cially available protected amino acids.
To allow pyrophosphate introduction, di-tert-butyl phos-
phate protective groups in the immobilized 39 were removed
with TFA and DCM, followed by neutralizing with pyridine. A
reaction of the obtained phosphate monoester 40 with phos-
phoramidite 41 under the influence of activator ETT was fol-
lowed by the oxidation of the PIII–PV intermediate with CSO
and, finally, the cyanoethyl group in the pyrophosphate was
removed with DBU. Target pyrophosphate 42 was obtained by
a two-step procedure. First, cleavage from the resin was
attained by treatment with a saturated NH3 solution in trifluoro-
ethanol. In this way the formation of a carboxylic acid at the
C-terminus of the peptide is circumvented and only carboxa-
Scheme 4 Ribosylated amino acids with a phosphotriester at 5-OH.
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mide is produced. Addition of NH4OH eﬀected the removal of
all remaining protective groups giving hendecapeptide 42.
This is the first reported synthesis of an ADP-ribosylated
peptide on serine,10 which has been found to be one of the
most widespread ADPr-modification sites in histones, upon
DNA damage.20–23 It is also the first real, naturally occurring
ADP-ribosylated oligopeptide as all others are provided with
stabilized anomeric ribosyl linkages, that is, asparagine (Asn)
and glutamine (Gln)8,9 as stabilized analogues of aspartic acid
(Asp) and glutamic acid (Glu), respectively.
Moyle and Muir24 reported the synthesis and a biochemical
evaluation of stabilized and artificial mono-ADP-ribose conju-
gated peptides. An N-terminal (3–19) oligopeptide24 of histone
H2B protein with the glutamate residue mono-ADP-ribosylated
was selected as a model (Scheme 6). With the aid of manual
SPPS on MBHA resin using HBTU/DIPEA, oligopeptides 45
and 46 having either an aminooxy or N-methyl aminooxy func-
tionality were assembled. The aminooxy-containing building
block 4325 or N-methyl aminooxy containing amino acid 4426
was incorporated instead of the glutamic acid at the
N-terminus. After cleavage from the resin the (N-methyl)
aminooxy groups in the oligopeptides 45 and 46 were reacted
with the hemiacetal of the ribose moiety in free ADP-ribose 47
producing an ADPr appendage. The aminooxy group in 45 led
mainly to ring-opened ADPr peptide 48 and a small amount of
the ring-closed form 49, while the N-methyl aminooxy group
in 46 gave the ring-closed ADPr peptide 50 exclusively. By
executing the ligation procedure at pH 4.5 the oxime formation
becomes selective, leaving all natural amino acid side-chain
functionalities, including those of lysine and arginine resi-
dues, intact.
Liu et al.27 reported another type of ADPr analogue that
can be easily introduced in oligopeptides with the aid of a
copper-catalyzed azide–alkyne cycloaddition (CuAAC) to give
triazole-linked ADP-ribosylated peptides (Scheme 7). With
the assistance of SPPS and standard amino acid building
blocks, either azido-alanine or azido-homoalanine was incor-
porated at specific positions of peptides, the sequences of
which were based on those of biologically relevant ADP-ribo-
sylated proteins. Both azido functionalized oligopeptides
(54a–d) and ubiquitin protein 54e in which Arg42 was
replaced by azido-homoalanine were assembled by standard
SPPS. After cleavage from the resin and concomitant removal
of all protecting groups, followed by purification with
RP-HPLC, peptides 54a–e were subjected to the critical
CuAAC reaction with alkyne 53. This ADPr building block was
eﬃciently prepared by the reaction of imidate donor 21a with
propargyl alcohol. Isolation of the pure α-anomer, followed
by protective group manipulation gave glycoside 51. Next,
phosphitylation, oxidation to the phosphodiester and
removal of the tBu protecting groups gave phosphomonoester
52 that was used in combination with phosphoramidite 41 to
provide pyrophosphate 53 via the same PIII–PV procedure19 as
described for the synthesis of the Ser-ADPr hendecapeptide
in Scheme 5. The CuAAC reaction of 53 with 54a–e in Tris
buﬀer at pH 7.6 under the influence of CuSO4, sodium ascor-
bate and a tris-triazole ligand proceeded eﬃciently to give tri-
azole-linked adenosine diphosphate ribosylated peptides 55.
The CuAAC reaction of 53 proved to be successful for small
proteins as illustrated by the total chemical synthesis of a
biologically active ADP-ribosylated ubiquitine derivative,
demonstrating that triazole linked ADPr can be employed
as bio-isosteres of ADPr-Arg in peptides or proteins
(Scheme 7).27 A diﬀerent CuAAC mediated approach to the
synthesis of triazole linked peptides has been reported by
Li et al.28
Scheme 5 SPPS of Ser-ADPr hendecapeptide originating from histone H2B.
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Scheme 6 The aminooxy and N-methyl aminooxy functionalized peptides 48–50 of the group of Muir.
Scheme 7 Synthesis of triazole linked ADPr-peptides by CuAAC chemistry.
Organic & Biomolecular Chemistry Review
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2.2 Synthesis of poly-ADPr chain
The organic synthesis of fragments of poly-ADP-ribose (PAR,
Fig. 1) comprises a repetitive introduction of both an
α-glycosidic bond between the ribose and the 2′-OH of adeno-
sine and a pyrophosphate linkage between the primary OHs of
the adenosine and the ribose moiety. To acquire ADPr oligo-
mers of a certain length both solution and solid phase
approaches require the design and synthesis of suitably pro-
tected and functionalized building blocks. Monomeric build-
ing blocks could be envisaged, in which a pyrophosphate
moiety is incorporated but these must then act as ADP-ribofur-
anosyl donors that are suitable for repetitive α-ribosylation of
the 2′-OH of the terminal adenosine moiety of the growing
PAR-chain. Although, such a method would resemble the bio-
synthesis of PAR, in which NAD+ fulfills the role of the ADP-
ribofuranosyl donor this approach should be rejected because
the repetitive introduction of multiple α-ribosidic bonds in the
presence of (anionic) pyrophosphates is almost impossible.
Therefore the α-ribosidic bond should be preinstalled in the
building block while the pyrophosphate moiety is then repeti-
tively introduced during the assembly of the oligo-ADP-ribose
chain. Both syntheses of ADP-ribose oligomers that are
reported to date use the latter strategy.18,29
In the following sections, we first describe the methods that
have been developed for the synthesis of 2′-O-ribosylated ade-
nosine building blocks (section 2.2.1), and next, the methods
of pyrophosphate formation in the framework of the assembly
of fragments of poly-ADPr-ribose will be discussed (section
2.2.2).
2.2.1 Building block synthesis–ribosylated adenosine. In
2008 Mikhailov et al.30 reported the first synthesis of a 2′-O-
α-D-ribofuranosyladenosine building block (60, Scheme 8). The
potentially problematic α-ribosylation was circumvented by the
use of 1-O-acetyl-2,3,5-tri-O-benzoyl-D-arabinofuranose 57 as a
donor. Condensation of donor 57 with adenosine acceptor 56
under the influence of tin tetrachloride aﬀorded, by neigh-
boring group participation, trans-configured disaccharide
nucleoside 58. To obtain 2′-O-α-D-ribofuranosyladenosine
building block 60, the route of synthesis was continued by
protective group manipulation and finally by inversion of 2′-
OH to give the desired ribo-configuration via an oxidation–
reduction sequence. The protective groups in building block
60 were removed to produce 2′-O-α-D-ribofuranosyladenosine
61. The group of Marx31 applied this method for the prepa-
ration of ribosylated adenosine analogues to develop PARP
inhibitors.
Although the method of Mikhailov et al.30 is robust the
route of synthesis to a monomeric building block suitable for
the assembly of oligo-ADP-ribose is rather lengthy due to the
necessity to invert the 2′-OH position of ribose and the sub-
sequent introduction of orthogonal protective groups. For the
synthesis of oligo-ADP-ribose, more direct approaches to attain
α-selective glycosylation of adenosine were developed. Van der
Heden van Noort et al.33 reported the synthesis of 2′-O-α-D-ribo-
sylated adenosine (64, Scheme 9A) with TBDPS and DMT as
orthogonal protecting groups on the primary hydroxyl func-
tions of the ribose moieties. The key step is the TMSOTf
mediated condensation of (N-phenyl)-2,2,2-trifluoroacetimi-
date donor 21c and adenosine acceptor 62 to furnish fully pro-
tected ribofuranosyladenosine 63 in an α-selective manner.
Subsequent protecting group manipulation yielded 64, amen-
able for the assembly of oligo-ADP-ribose. Recently, Shirinfar
et al.32 reported the synthesis of a protected phosphorylated
ribofuranosyladenosine building block, using the same glyco-
sylation procedure.
In 2015 Lambrecht et al.29 reported the synthesis of orthog-
onally protected ribosyl adenosine 67 (Scheme 9B) by the
α-selective condensation of β-fluoride donor 66, obtained in
six steps from ribose with adenosine acceptor 65. Crucial for
the productivity of this reaction was the use of AgPF6/SbCl2 as
an activator combination.
Scheme 8 Synthesis of 2’-O-α-ribosylated adenosine 61 using 1-O-acetyl-2,3,5-tri-O-benzoyl-D-arabinofuranose 57 as the donor.
Review Organic & Biomolecular Chemistry
5468 | Org. Biomol. Chem., 2019, 17, 5460–5474 This journal is © The Royal Society of Chemistry 2019
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
M
ay
 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
/1
2/
20
20
 9
:3
6:
37
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Guided by the need to scale up the process and to acquire
suﬃcient quantities of a suitable ribosyl-adenosine building
block Kistemaker et al.18 developed a new method. Side reac-
tions on the nucleobase often accompany the glycosylation of
protected nucleosides limiting the scalability of such synthetic
strategies.33 Therefore it was decided to install the adenine
base by a Vorbrüggen reaction after the ribosylation event.34,35
As depicted in Scheme 10 a reaction of benzylated (N-phenyl)-
2,2,2-trifluoroacetimidate donor 21b and commercially avail-
able acceptor 1,3,5-tri-O-benzoylribose 68 led to the isolation
of α-configured disaccharide 69. After hydrogenolysis and
acetylation, 70 was obtained. Vorbrüggen coupling of 70 and
Bz-adenine under the influence of the immobilized acid
(HClO4-SiO2), introduced the adenine base both regio- and
β-stereoselectively. It is noteworthy that this approach gives
access to a large amount of 71, the precursor of a suitable 2-O-
ribosylated adenosine building block.
This glycosylation strategy was adopted towards the syn-
thesis of the branching point of ADPr-chains, culminating in
the construction of both unphosphorylated36 and tripho-
sphorylated37 branched ADPr fragments. The assembly of O-
α-D-ribofuranosyl-(1′′′ → 2″)-O-α-D-ribofuranosyl-(1″ → 2′)-ade-
nosine-5′,5″,5′′′-tris(phosphate) 77 is depicted in Scheme 11.
Protected disaccharide 69, termed parobiose,37 was converted
into 72, in which the non-reducing ribose is provided with a
free 2-OH group. Subsequent TMSOTf mediated condensation
of 72 with benzylated (N-phenyl)-2,2,2-trifluoroacetimidate
donor 21b led to all alpha configured tri-riboside 73 (protected
parotriose).37 After protective group manipulation the adenine
base was introduced through a similar Vorbrüggen type glyco-
sylation as described above to aﬀord protected O-α-D-ribofura-
nosyl-(1′′′ → 2″)-O-α-D-ribofuranosyl-(1″ → 2′)-adenosine 75.
Transformation of 75 to 76 allowed the three-fold introduction
of di-tert-butyl-phosphotriesters with the aid of phosphorami-
Scheme 9 Synthesis of orthogonally protected ribosylated adenosine with (A): 1-O-(N-phenyl)-2,2,2-triﬂuoroacetimido-2,3,5-tri-O-benzyl-D-ribo-
furanose 21c and (B): glycosyl ﬂuoride 66 as the donors.
Scheme 10 Synthesis of ribosylated adenosine via Vorbrüggen type glycosylation.
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dite chemistry. Treatment of 76 with 10 equivalents of di-tert-
butyl-N,N-diisopropylphosphoramidite under the influence of
1-methylimidazole and 1-methylimidazolium chloride as the
activator, followed by oxidation of the intermediate phosphite
triesters and global deprotection yielded target triphosphate
77 which proved to be identical to the native structure38,39 as
ascertained by NMR spectroscopy.
2.2.2 Synthetic approaches to oligo-ADPr. Pyrophosphates
are important functional groups in a wide array of naturally
occurring compounds and a lot of procedures for the synthesis
of pyrophosphates have been reported.19,40–48 However, the
occurrence of multiple pyrophosphates in one molecule, such
as in oligo-ADPr, is unprecedented and presents a special chal-
lenge. Only two syntheses of short fragments of oligo-ADPr
have been published to date. Lambrecht et al.29 (Scheme 12)
reported a solution phase synthesis of an ADPr dimer, in
which they relied on the classic Atherton–Todd chemistry to
construct pyrophosphate bridges.29 In their route of synthesis
ribosylated adenosine building block 67, obtained as
described above (Scheme 9), was subjected to protective group
Scheme 11 Synthesis of O-α-D-ribofuranosyl-(1’’’ → 2’’)-O-α-D-ribofuranosyl-(1’’ → 2’)-adenosine-5’,5’’,5’’’-tris(phosphate): the branching point of
ADPr-chain.
Scheme 12 Synthesis of ADPr dimer 83 by Lambrecht et al.
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manipulation to allow the installation of a dibenzyl phospho-
triester at the primary OH of adenosine with the aid of phos-
phoramidite chemistry and subsequent oxidation. The
naphthyl ether at the 5′-OH of the ribose moiety in thus
obtained 78 was selectively removed and a H-phosphonate
diester was introduced with 2-cyanoethyl N,N-diisopropyl-
chlorophosphoramidite and subsequent hydrolysis of the
intermediate phosphoramidite to give 79. Oxidative chlori-
nation of H-phosphonate of 79 with NCS aﬀorded an inter-
mediate chlorophosphate which was condensed with adeno-
sine monophosphate 80 to give after the removal of the cya-
noethyl group pyrophosphate 81 (R = Bn) in good yield.
Hydrogenolysis of the benzyl group aﬀorded terminal phos-
phate 81 (R = H). Unfortunately, the introduction of the
second pyrophosphate with the same method failed. Therefore
silylated ribose monophosphate 82 was treated with CDI and
condensation of the resulting phosphorimidazolide with 81 (R
= H) gave after the removal of all protecting groups the target
ADP dimer 83 in good yield.
Kistemaker et al. reported a solid phase synthesis of both
an ADPr dimer and trimer (Scheme 14).18 To be able to intro-
duce multiple pyrophosphates a method to access sugar-
nucleotides which was based on the combination of PIII–PV
chemistry was investigated.19 This methodology proved to be
convenient and expedient not only for the synthesis of mono-
ADP-ribosylated peptides (Scheme 5) but also for the synthesis
of various bioorganic pyrophosphate derivatives both in
solution47,49,50 and on the solid phase.51,52 It was expected that
this PIII–PV method would be uniquely suitable for the
repeated pyrophosphorylation on the solid phase, not least
due to its mild nature and fast kinetics. To be able to intro-
duce multiple pyrophosphate functions building block 86, pro-
vided with di-tert-butyl phosphotriester and 2-cyanoethyl N,N-
diisopropylphosphoramidite, was designed. The synthesis of
building block 86 (Scheme 13) started with 2-O-ribosyladeno-
sine 71 which was obtained in suﬃcient quantities and good
yield as described above (Scheme 10). Protective group
manipulation of dimer 71 gave 84 in which the free primary
OH in the ribose moiety was provided with a di-tert-butyl phos-
photriester using standard phosphoramidite chemistry, fol-
lowed by oxidation of the intermediate phosphite triester.
Finally, removal of the DMT group to give 85 and a reaction
with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite
resulted in the isolation of building block 86 that contains
both a phosphoramidite and a protected precursor of the
phosphate monoester.
Scheme 13 Synthesis of ribosylated adenosine building block 86 suitable for solid-phase preparation of oligo-ADPr fragments.
Scheme 14 Solid-phase synthesis of ADPr dimer 89 and trimer 90.
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The solid phase synthesis of an ADPr dimer 89 and trimer
90 using building block 86 and terminating building block 88
is shown in Scheme 14.
Guided by the state of the art in automated DNA synthesis,
controlled pore glass (CPG)18 with long alkyl amine chains was
used as the solid support while hydroquinone-O,O′-diacetic acid
(Q-linker) was selected as a linker for its improved resistance to
DBU that was used to cleave 2-cyanoethyl protection from the
pyrophosphate. Functionalization of this solid support with pro-
tected ribose and introduction of the phosphate monoester at
the primary position gave “initiator” 87. At this stage, up to two
coupling cycles with building block 86 were undertaken. The
coupling cycle took one hour and involved 5-ethylthiotetrazole
(ETT) mediated condensation of 80 with the immobilized
monophosphate, oxidation of the obtained labile phosphite–
phosphate (PIII–PV) intermediate by (1S)-(+)-(10-camphorsulfo-
nyl)oxaziridine (CSO), and removal of the 2-cyanoethyl group in
the partially protected pyrophosphate intermediate with DBU.
The final unmasking of the di-tert-butyl phosphotriester with
HCl/HFIP followed by neutralization with pyridine allowed the
next elongation with either 86 or terminating building block 88.
The immobilized and partially protected ADPr dimer and
trimer were cleaved from the resin and completely deprotected
by treatment with aqueous ammonia and purified to give milli-
gram quantities of ADPr dimer 89 and trimer 90.
3. Conclusions and outlook
It can be concluded that significant progress has been
achieved in the last ten years towards the synthesis of both
mono-ADPr peptides and oligo-ADPr.
For the synthesis of mono-ADPr-peptides most successes
have been achieved in the preparation of the constructs, in
which the ADPr-moiety is attached to the peptide backbone via
isosteres of the natural amino acids either close, such as Gln9
instead of native Glu, or remote,22 for example, a triazole
linkage27 as a substitute for the arginine side chain. Native
ADPr-Ser containing peptides10 have been synthesized never-
theless. A fully synthetic ADPr-protein has been prepared via a
convergent approach based on copper-catalyzed click chem-
istry and has been shown to be biologically active.27 The syn-
thetic ADPr-peptides have been extensively applied in
biochemical9,53 and proteomics studies.54–56 Thus, ADPr-pep-
tides have been used as the essential calibration standard to
enable quantification of ADP-ribosylation in the proteome.54,55
Another application of the synthetic ADPr-peptides is to vali-
date the pull-down steps in the ELTA-methodology that has
been developed for selective labeling of ADP-ribose and ADP-
ribosylated proteins.57 Concerning the synthetic ADPr-oligo-
mers, the dimeric ADPr was cocrystallized with PARG to inves-
tigate the details of the mechanism of the catalytic action of
this enzyme. The synthetic dimeric and trimeric ADPr frag-
ments were essential for determining the minimum length of
PAR necessary to bind ALC1, which is a chromatin remodeler
involved in oncogenesis.53 Looking towards the future appli-
cations, one can envisage the use of synthetic ADPR-oligomers
in experiments for which less well-defined and, arguably, less
homogeneous PAR-fragments of a biological origin have been
applied up to now.58–61 Future synthetic studies will probably
focus on the native ADP-ribosylated peptides, containing
ADPr-Arg, ADPr-Cys, ADPr-Tyr and ADPr-His as the ADP-ribosy-
lation sites. To make the synthesis of ADPr-peptides more
practical, it is imperative to develop a synthetic methodology
that does not require significant alterations in the standard
SPPS protocols such as the use of alkali labile side-chain pro-
tection and linkers. Another important avenue of research is
the development of more chemically robust derivatives, for
example, mono-ADPr-peptides that contain carba-ribose62 resi-
dues instead of native ribofuranose and methylene bispho-
sphonate63 as pyrophosphate isosteres. Such stabilized deriva-
tives of ADP-ribosylated biomolecules may prove invaluable for
structural studies on the native enzymes because one can then
forego the use of catalytically inactive mutants.64 Methylene
bisphosphonates have been used in the past as substitutes of
the native pyrophosphate in studies aimed to generate anti-
bodies for mono-ADP-ribosylated proteins.65 It has been found
that rendering the native pyrophosphate nuclease resistant by
converting it into methylene bisphosphonate was essential to
raise antibodies against ADP-ribose.
Both solid-phase18 and solution29 methodologies have been
published for the synthesis of ADPr-dimers. It seems, however,
that the solid-phase synthesis is more practical as evident
from the fact that tri-ADPr was prepared using a solid-phase
approach. Various methods toward the introduction of the key
α-glycosidic bond that connects the monomers in the ADPr-
chain have been explored. It appears that the methods that
involved direct glycosylation of the 2′-OH of ribose, whether in
the absence of the adenine nucleobase or having the nucleobase
preinstalled, are the most useful ones for the monomer syn-
thesis. In particular, glycosylation of the 2-OH of ribose followed
by the introduction of adenine via Vorbrüggen type condensation
allowed the preparation of the branching point of the ADPr-
chain.36,37 Up to now, the P(III)–P(V) approach to pyrophosphate
formation19 has been proven to be suitable for the synthesis of
the ADPr-chains up to trimers on a solid phase, while the classic
method of pyrophosphate formation allowed the synthesis of di-
ADPr in solution. Such short fragments already proved to be
useful in the biochemical53 and structural studies.29
Further developments in the methodology of chemical ADP-
ribosylation can be envisaged. Improved temporal protective
groups for phosphate monoesters should enable the synthesis
of longer ADPr-chains, perhaps up to 15–25 ADPr units long.
Various resins, such as polystyrene-based resins, could be
explored for scale up and the preparation of oligo-ADPr frag-
ments grafted to peptides. The synthesis of branched oligo-ADPr
and ADPr-chains attached to peptides should also be possible.
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